Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndrome
Chen‐Yen Yang(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco), Taha Rakhshandaroo, Shervin Afghani(University of California, Berkeley), Laura B. Pincus(University of California, San Francisco), Sourav Bandyopadhyay(University of California, San Francisco), Frank McCormick(Frederick National Laboratory for Cancer Research), Razan Faraj(Emory University)
Cited by 0
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
|Cancer Cell|2013|571
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487